Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 10 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

4 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 1
5(50.0%)
Phase 3
4(40.0%)
Phase 2
1(10.0%)
10Total
Phase 1(5)
Phase 3(4)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials
NCT05262010Phase 3Recruiting

A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years

Role: collaborator

NCT05050474Phase 1Completed

Booster Immunization Study of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)

Role: collaborator

NCT04644484Phase 3Completed

A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety

Role: collaborator

NCT04436133Phase 2Completed

Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)

Role: collaborator

NCT04083196Phase 1Completed

A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years

Role: collaborator

NCT04108845Phase 1Unknown

Safety Study of 15-Valent Pneumococcal Conjugate Vaccine in Healthy Volunteers Aged Above 2 Months

Role: collaborator

NCT01979900Phase 3Completed

Phase III Clinical Study of Efficacy and Safety of Vaccae™ to Prevent Tuberculosis

Role: collaborator

NCT02964065Phase 3Completed

A Trial on the Efficacy, Safety and Immunogenicity of Live-Attenuated Influenza Vaccine (LAIV)

Role: collaborator

NCT02919293Phase 1Unknown

Immunogenicity and Safety of Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to 5 Months of Age

Role: collaborator

NCT02878291Phase 1Unknown

Safety Study of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months

Role: collaborator

All 10 trials loaded